KDR and neoplasm: Therefore, although the combination of toripalimab and VEGFR inhibitory therapy has shown some efficacy, there may be additional complexities in the immune escape mechanisms and vascular remodelling of tumours, which may lead to greater variation in the efficacy of this combination in different patient groups.